经尿道1470 nm激光切除术与TURis治疗非肌层浸润性膀胱癌的疗效比较
|
摘要
目的对比经尿道1 470 nm激光切除术与经尿道双极等离子电切术(TURis)治疗非肌层浸润性膀胱癌(NMIBC的应用价值。方法回顾性分析2016年7月至2018年6月我院156例NMIBC患者的临床资料,根据治疗术式分为激光组(n=74,经尿道1 470 nm激光切除术)和TURis组(n=82, TURis)。观察两组的手术情况、并发症情况及复发情况。结果激光组的手术时间、出血量、住院时间及并发症发生率均优于TURis组(P <0.05)。两组的术后复发率比较差异无统计学意义(P>0.05)。结论与TURis相比,经尿道1 470 nm激光切除术治疗NMIBC在改善手术情况、降低并发症发生率等方面更具优势。
Objective To compare the application value of transurethral 1 470 nm laser resection and transurethral resection in saline(TURis) in the treatment of non-muscle invasive bladder cancer(NMIBC). Methods The clinical data of 156 NMIBC patients in our hospital from July 2016 to June 2018 were retrospectively analyzed. They were divided into laser group(n = 74, transurethral 1 470 nm laser resection) and TURis group(n = 82, TURis) according to the treatment methods. The operation conditions, complications and recurrence of the two groups were observed. Results The operation time, blood loss, hospitalization time and incidence of complications of the laser group were better than those of the TURis group(P <0.05). No statistical difference was found in the postoperative recurrence rate between the two groups(P >0.05). Conclusions Compared with TURis, transurethral 1 470 nm laser resection in the treatment of NMIBC is more advantageous in improving the operation conditions and reducing the incidence of complications.
Objective To compare the application value of transurethral 1 470 nm laser resection and transurethral resection in saline(TURis) in the treatment of non-muscle invasive bladder cancer(NMIBC). Methods The clinical data of 156 NMIBC patients in our hospital from July 2016 to June 2018 were retrospectively analyzed. They were divided into laser group(n = 74, transurethral 1 470 nm laser resection) and TURis group(n = 82, TURis) according to the treatment methods. The operation conditions, complications and recurrence of the two groups were observed. Results The operation time, blood loss, hospitalization time and incidence of complications of the laser group were better than those of the TURis group(P <0.05). No statistical difference was found in the postoperative recurrence rate between the two groups(P >0.05). Conclusions Compared with TURis, transurethral 1 470 nm laser resection in the treatment of NMIBC is more advantageous in improving the operation conditions and reducing the incidence of complications.
引文
[1]曾甫清,蒋国松.非肌层浸润性膀胱癌的规范治疗[J].临床泌尿外科杂志, 2015, 30(4):287-290.
[2]林瑞,杜君,张艳辉,等. EORTC危险评分系统对T1期非肌层浸润性膀胱癌患者的预后评价[J].中国肿瘤临床, 2016, 43(15):655-658.
[3]郭佳,刘修恒,胡云飞,等.直出1470nm半导体激光膀胱肿瘤剜除术治疗膀胱癌的疗效及安全性研究[J].国际泌尿系统杂志, 2016,36(6):805-807.
[4]王善龙,贺利明,张永升,等.经尿道钬激光切除术与等离子电切术治疗非肌层浸润性膀胱肿瘤的疗效及安全性对比[J].实用癌症杂志, 2017, 32(8):1345-1347.
[5]文瀚东,王涛,潘铁军,等. 1470nm半导体激光局部切除治疗老年高危膀胱癌的临床价值探讨[J].现代泌尿生殖肿瘤杂志, 2018,10(1):13-15.
[6]李功成,潘铁军,文瀚东,等. 1470nm激光经尿道膀胱肿瘤整块切除疗效观察[J].临床泌尿外科杂志, 2017, 32(4):25-27.
[7]叶明宝,杜昌国,燕群峰,等.两种不同方法治疗非肌层浸润性膀胱癌疗效比较[J].海南医学, 2017, 27(8):1338-1339.
[8] Hermann GG, Mogensen K, Rosthoj S. Outpatient diode laser treatment of intermediate-risk non-invasive bladder tumors without sedation:efficacy, safety and economic analysis[J]. Scand J Urol, 2018,52(3):194-198.
[2]林瑞,杜君,张艳辉,等. EORTC危险评分系统对T1期非肌层浸润性膀胱癌患者的预后评价[J].中国肿瘤临床, 2016, 43(15):655-658.
[3]郭佳,刘修恒,胡云飞,等.直出1470nm半导体激光膀胱肿瘤剜除术治疗膀胱癌的疗效及安全性研究[J].国际泌尿系统杂志, 2016,36(6):805-807.
[4]王善龙,贺利明,张永升,等.经尿道钬激光切除术与等离子电切术治疗非肌层浸润性膀胱肿瘤的疗效及安全性对比[J].实用癌症杂志, 2017, 32(8):1345-1347.
[5]文瀚东,王涛,潘铁军,等. 1470nm半导体激光局部切除治疗老年高危膀胱癌的临床价值探讨[J].现代泌尿生殖肿瘤杂志, 2018,10(1):13-15.
[6]李功成,潘铁军,文瀚东,等. 1470nm激光经尿道膀胱肿瘤整块切除疗效观察[J].临床泌尿外科杂志, 2017, 32(4):25-27.
[7]叶明宝,杜昌国,燕群峰,等.两种不同方法治疗非肌层浸润性膀胱癌疗效比较[J].海南医学, 2017, 27(8):1338-1339.
[8] Hermann GG, Mogensen K, Rosthoj S. Outpatient diode laser treatment of intermediate-risk non-invasive bladder tumors without sedation:efficacy, safety and economic analysis[J]. Scand J Urol, 2018,52(3):194-198.